Invitrogen™ Rovalpituzumab Humanized Recombinant Human Monoclonal Antibody

Catalog No.	Quantity
PIMA542077	100 μg

Catalog No. PIMA542077

Supplier: Invitrogen™ MA542077

Description

Human Recombinant Monoclonal Antibody

Endotoxin level < 0.01EU/μg by LAL method Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8 °C for one week. Store at -20 to -80 °C for twelve months from the date of receipt.

Rovalpituzumab is a biosimilar that targets DLL3. Delta-like protein 3 (DLL3) is a ligand for the Notch signaling pathway. It inhibits primary neurogenesis. DLL3 plays a role in the formation of somite boundaries during segmentation of the paraxial mesoderm. Defects in DLL3 are the cause of Spondylocostal dysostosis autosomal recessive type 1 (SCDO1). Mutations in DLL3 gene cause truncal shortening relative to their limbs, which leads to abdominal protrusion, abnormal spinal curvature and sometimes a plagiocephaly-torticollis sequence. It may be required to divert neurons along a specific differentiation pathway.

Specifications

• Antigen: Rovalpituzumab Humanized
• Applications: ELISA
• Classification: Recombinant Monoclonal
• Concentration: 2.53 mg/mL
• Conjugate: Unconjugated
• Formulation: PBS with no preservative; pH 7.4
• Gene Alias: Rovalpituzumab tesirine; Rova-T
• Host Species: Human
• Immunogen: Human DLL3.
• Purification Method: Protein A
• Quantity: 100 μg
• Regulatory Status: RUO
• Primary or Secondary: Primary
• Target Species: Human
• Content And Storage: -20°C, Avoid Freeze/Thaw Cycles
• Product Type: Antibody
• Form: Liquid
• Isotype: IgG1 κ
• Target Molecule: Chemical

Safety and Handling

WARNING: Cancer - www.P65Warnings.ca.gov